Odyssey Therapeutics Appoints Julie Clauss as Chief Operating Officer and Christopher Butler as SVP, Head of Chemistry

Odyssey Therapeutics, Inc. , a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, today announced the appointment of Julie Clauss, MBA, as chief operating officer and Christopher Butler, Ph.D., as senior vice president (SVP), head of Chemistry.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, April 2, 2024
Information
Tags: 
Biotechnology, FDA, Health, General Health, Pharmaceutical, Oncology, Research, Infectious Diseases, Genetics, Science, Clinical Trials, Culture, Sanofi Pasteur, Drug discovery, Business administration, Patient, SVP, Gene, Joseph Fourier University, Standard of care, Cancer, University, Record, Inflammation, MBA, Therapy, Sloan Fellows, Research and development, Multimedia, Vertex Pharmaceuticals, Physical, Management
Geotags: 
UNITED STATES, NORTH AMERICA, MASSACHUSETTS, ILLINOIS
⚠ partially generated by AI ↴
Organisation: 
ODYSSEY THERAPEUTICS, ODYSSEY THERAPEUTICS, INC.
Summary
Key Points: 
  • Odyssey Therapeutics, Inc. , a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, today announced the appointment of Julie Clauss, MBA, as chief operating officer and Christopher Butler, Ph.D., as senior vice president (SVP), head of Chemistry.
  • Together, these individuals bring more than 40 years of leadership experience and scientific expertise within the biotechnology and pharmaceutical industries to Odyssey.
  • Clauss and Dr. Butler have proven track records of successfully leading teams to achieve strategic business and research goals.
  • Ms. Clauss received a Master of Business Administration through the Sloan Fellows program at the Massachusetts Institute of Technology.


Odyssey Therapeutics, Inc., a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, today announced the appointment of Julie Clauss, MBA, as chief operating officer and Christopher Butler, Ph.D., as senior vice president (SVP), head of Chemistry. Together, these individuals bring more than 40 years of leadership experience and scientific expertise within the biotechnology and pharmaceutical industries to Odyssey.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240402747244/en/

Julie Clauss, chief operating officer (Photo: Business Wire)

Julie Clauss, chief operating officer (Photo: Business Wire)

“As we take extraordinary leaps to improve patient outcomes, we continue to recruit the best and brightest to join our team,” said Gary D. Glick, Ph.D., founder and CEO of Odyssey Therapeutics. “Ms. Clauss and Dr. Butler have proven track records of successfully leading teams to achieve strategic business and research goals. With their backgrounds, we will continue to push new frontiers in drug discovery and development for patients living with serious diseases.”

Ms. Clauss will oversee Odyssey’s business, administrative and clinical operations, providing cross-functional leadership to each of these critical functions. She will work closely with the executive team to drive operational excellence and support the realization of Odyssey’s vision of delivering transformative medicines to advance the standard of care for patients living with immune diseases and cancer. Previously, Ms. Clauss served as the vice president and lead for the Gene Therapy Platform at Ultragenyx, aligning functions across programs and driving operational efficiency, as well as the vice president and head of Research and Development (R&D) Operations at Ipsen Bioscience, establishing the strategic portfolio management group and developing data-driven global R&D strategies. Her career also includes leadership positions at Sanofi Pasteur and Sanofi. Ms. Clauss received a Master of Business Administration through the Sloan Fellows program at the Massachusetts Institute of Technology. She holds a Master of Engineering degree from Ecole Centrale Mediterranee and a Master of Science degree in Chemistry and Physical Sciences from Joseph Fourier University.

“At Odyssey, I aim to leverage my leadership experience to help drive innovation, align functions and enhance operational efficiency to achieve meaningful, patient-centric solutions,” said Ms. Clauss. “Odyssey is advancing a pipeline of medicines with exceptional potential, and I look forward to collaborating with passionate colleagues to help realize the company’s mission.”

As SVP and head of Chemistry, Dr. Butler will play a pivotal role in shaping the strategic direction of the company's research efforts, driving innovation and fostering a culture of excellence within the chemistry department. Prior to joining Odyssey, he held various leadership positions at Vertex Pharmaceuticals and Pfizer. Dr. Butler earned his Ph.D. in organic chemistry at the University of Illinois Urbana-Champaign and has published numerous papers and received several awards for his research efforts related to synthetic and medicinal chemistry.

“I was drawn to Odyssey because of the breadth and depth of its talented scientists and leadership, as well as its relentless investment in data sciences, chemistry and research,” said Dr. Butler. “As expert drug hunters, they are at the forefront of scientific discovery, working to stay ahead of inflammatory diseases and cancer, and solve problems to get medicines to patients faster.”

About Odyssey Therapeutics

Odyssey Therapeutics is a biotechnology company focused on discovering, developing and commercializing the next generation of immunomodulators and oncology medicines. Composed of an expert team of drug hunters, scientists and industry leaders in foundational biology, chemistry and data sciences, Odyssey is transforming drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients. For more information, please visit odysseytx.com and follow Odyssey Therapeutics on X (formerly Twitter) and LinkedIn.

Copyright: 
Copyright Business Wire 2024